Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Tcm cells in metastatic bladder cancer
NCT03389438Phase 2Terminated
- Sponsor
- Beijing Chaoyang Huanxing Cancer Hospital
- Start
- Feb 2018
- Primary completion
- Feb 2021
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in bladder urothelial carcinoma (2 arms), sponsored by Beijing Chaoyang Huanxing Cancer Hospital. Primary endpoint: Progression-free Survival at 12 weeks. Started Feb 2018; status: terminated.
02
Conditions
bladder urothelial carcinoma
Beyond the preview
Go deeper on NCT03389438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03389438.